Results 11 to 20 of about 1,786 (140)
Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases [PDF]
Sexual Medicine, 2016 Introduction: Ospemifene (Osphena, Shionogi Inc, Florham, NJ, USA) is an estrogen agonist and antagonist approved by the U.S. Federal Drug Administration for the treatment of “moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due ...
Andrew T. Goldstein, MD +1 more
doaj +2 more sources
Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey [PDF]
Climacteric, 2016 Objectives The aim of the European REVIVE survey was to achieve a better understanding of vulvovaginal atrophy (VVA), a chronic and progressive condition after menopause.
Nick Panay +2 more
exaly +3 more sources
Treatment of vulvar pain caused by atrophy: a systematic review of clinical studies [PDF]
Clinical and Experimental Obstetrics & Gynecology, 2021 Background: The signs and symptoms of the genitourinary syndrome of menopause are well established, and there is extensive knowledge with high scientific evidence about the response that vaginal and urinary tissues present to various treatments. However,
Sonia Sánchez +2 more
doaj +2 more sources
Acta Obstetricia et Gynecologica Scandinavica, 2022 In recent years, LASER has been introduced as a minimally invasive treatment for a broad range of vaginal and vulvar symptoms and diseases. However, the efficacy and safety of vaginal and vulvar LASER has continuously been questioned.
Olivia Engholt Mortensen +2 more
doaj +2 more sources
Management of Vaginal Atrophy: Implications from the REVIVE Survey
Clinical Medicine Insights: Reproductive Health, 2014 Vulvar and vaginal atrophy (VVA) is a chronic and progressive medical condition common in postmenopausal women. Symptoms of VVA such as dyspareunia, vaginal dryness, irritation, and itching can negatively impact sexual function and quality of life.
Susan Wysocki +2 more
doaj +2 more sources
Current management of vaginal dryness [PDF]
РМЖ. Мать и дитя, 2021 T.V. Tazina1, A.V. Knyazeva2, T.V. Bebneva3,4 1Ryazan State Medical University, Ryazan, Russian Federation 2Regional Clinical Hospital, Ryazan, Russian Federation 3Russian University of Peoples’ Friendship, Moscow, Russian Federation ...
T.V. Tazina, A.V. Knyazeva, T.V. Bebneva
doaj +3 more sources
International Journal of Women's Health, 2013 Lin H Soe, Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, University of California, Davis, Sacramento, CA, USA Abstract: Ospemifene is a selective estrogen ...
Soe LH, Wurz GT, Kao CJ, DeGregorio MW
doaj +1 more source
Gynecological EndocrinologyBackground Thyroid autoimmune disorders (ADs) are common in midlife women and can impact various aspects of health, including sexual function. The effect of thyroid autoimmunity on the clinical manifestations of vulvovaginal atrophy (VVA) remains unclear.
Laura Cucinella +10 more
doaj +2 more sources
Management of patients with the atrophic variant of vulvar lichen sclerosus [PDF]
Гинекология, 2022 Aim.The objective is to optimize the diagnosis and management of the atrophic variant of the vulvar lichen sclerosus (LS). Materials and methods. We examined 58 female patients from 20 to 70 years old with the atrophic variant of the vulvar LS.
Ekaterina V. Kolesnikova +3 more
doaj +3 more sources
Vulvovaginal atrophy: modern approaches to diagnostics and management [PDF]
Zaporožskij Medicinskij ŽurnalThe aim of the review is to analyze the latest data on the current state of diagnosis and management of a common benign vulvar and vaginal disease in postmenopausal women – atrophic vulvovaginitis.
V. H. Siusiuka +4 more
doaj +2 more sources